Abstract
Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variation may modify the relationship between lifestyle behaviors and weight loss or weight gain. Similar observations have also emerged from pharmacogenetic studies. The literature includes several reports from these studies, but few examples of interactions have been adequately replicated. In this review we introduce the topics of population genetics and gene x environment interaction research. We also provide a systematic review of the published literature on gene x lifestyle (physical activity and dietary factors) and gene x drug interactions in relation to obesity. Finally, we overview the scope and findings from these studies and discuss some of their strengths and limitations.
Keywords: Genetic, gene x drug interaction, gene x lifestyle interaction, nutrition, nutriogenomics, obesity, pharmacogenetics, physical activity, cardiovascular disease, type 2 diabetes mellitus
Current Vascular Pharmacology
Title: Gene-Lifestyle and Gene-Pharmacotherapy Interactions in Obesity and Its Cardiovascular Consequences
Volume: 9 Issue: 4
Author(s): Paul W. Franks and Alaitz Poveda
Affiliation:
Keywords: Genetic, gene x drug interaction, gene x lifestyle interaction, nutrition, nutriogenomics, obesity, pharmacogenetics, physical activity, cardiovascular disease, type 2 diabetes mellitus
Abstract: Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variation may modify the relationship between lifestyle behaviors and weight loss or weight gain. Similar observations have also emerged from pharmacogenetic studies. The literature includes several reports from these studies, but few examples of interactions have been adequately replicated. In this review we introduce the topics of population genetics and gene x environment interaction research. We also provide a systematic review of the published literature on gene x lifestyle (physical activity and dietary factors) and gene x drug interactions in relation to obesity. Finally, we overview the scope and findings from these studies and discuss some of their strengths and limitations.
Export Options
About this article
Cite this article as:
W. Franks Paul and Poveda Alaitz, Gene-Lifestyle and Gene-Pharmacotherapy Interactions in Obesity and Its Cardiovascular Consequences, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197233
DOI https://dx.doi.org/10.2174/157016111796197233 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Angiogenesis-regulating microRNAs and Ischemic Stroke
Current Vascular Pharmacology Atrial Fibrillation: The Emerging Role of Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets Systemic Administration of Fluoro-Gold for the Histological Assessment of Vascular Structure, Integrity and Damage
Current Neurovascular Research Deciphering the Inactivation of Human Pancreatic α-Amylase, an Antidiabetic Target, by Bisdemethoxycurcumin, a Small Molecule Inhibitor, Isolated from Curcuma longa
The Natural Products Journal Metabolic Reprogramming of Human Cells in Response to Oxidative Stress: Implications in the Pathophysiology and Therapy of Mitochondrial Diseases
Current Pharmaceutical Design Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Platelet Function Testing in Atherothrombotic Disease
Current Pharmaceutical Design Upregulated Retinol Binding Protein and Transthyretin as Predictive Biomarkers of Gestational Diabetes Mellitus
Current Proteomics Malignant Hypertension: A Rare Problem or is it Underdiagnosed?
Current Vascular Pharmacology Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome
Current Pharmaceutical Design Potential of Plant Mucilages in Pharmaceuticals and Therapy
Current Drug Delivery Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Oxidative stress and Parkinson’s disease: New hopes in treatment with herbal antioxidants
Current Pharmaceutical Design Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Current Vascular Pharmacology Subject Index To Volume 4
Cardiovascular & Hematological Agents in Medicinal Chemistry Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Analysis and Validation of Differentially Expressed MicroRNAs with their Target Genes Involved in GLP-1RA Facilitated Osteogenesis
Current Bioinformatics Prevention of Cardiovascular Complications in the Marfan Syndrome
Vascular Disease Prevention (Discontinued) Delivery systems for biopharmaceuticals. Part II: Liposomes, Micelles, Microemulsions and Dendrimers
Current Pharmaceutical Biotechnology